Clinical Services

UF Health is using the knowledge gained from pharmacogenomics research to advance health care for our patients. Pharmacogenetic testing provides information about a person’s genetic profile that can be used to help identify the right medicine and the right dose, ideally before a patient starts taking a medication. UF Health providers at hospitals and clinics in Gainesville and Jacksonville are using genetic information alongside a patient’s medical history to inform treatment decisions in areas such as cancer, heart disease, gastrointestinal disorders and pain management.

Pharmacogenomics Consultation Service

The UF College of Pharmacy operates one of the nation’s first outpatient pharmacogenetics consultation service (MyRx) for UF Health. The virtual service brings pharmacogenetic testing to providers across the state of Florida.

Pharmacogenetics Service

Fast Facts

13,000+ patients genotyped

7 clinical implementations

23 hospitals and clinics have implemented pharmacogenomics testing

Clinical Implementations

JUNE 2012

CYP2C19 – clopidogrel (Gainesville)

CYP2C19 testing was implemented to predict clopidogrel response in patients undergoing percutaneous coronary intervention at UF Health Shands Hospital.

DNA Helix

FEBRUARY 2014

TPMT – thiopurines

TPMT genetic testing was implemented to predict response for patients taking a group of drugs known as thiopurines. Adult and pediatric patients with certain types of bowel or joint disorders and acute lymphoblastic leukemia commonly take thiopurines.

DNA Helix

JULY 2014

IFNL3-PEG-IFNα

IFNL3 testing was implemented to predict the PEG IFN-α-based drug regimen response for gastroenterology patients.

DNA Helix

MAY 2015

CYP2D6 – opioids

CYP2D6 testing was implemented to predict the response of pain management patients taking multiple opioids including tramadol, codeine, hydrocodone and oxycodone.

DNA Helix

april 2016

CYP2C19 – clopidogrel (Jacksonville)

CYP2C19 testing was implemented to predict clopidogrel response in patients undergoing percutaneous coronary intervention at UF Health Jacksonville

DNA Helix

OCTOBER 2016

CYP2D6 / CYP2C19 – SSRIs

CYP2D6 and CYP2C19 testing was implemented to predict response for psychiatric patients taking a group of drugs known as selective serotonin reuptake inhibitors, or SSRIs.

DNA Helix

JANUARY 2017

CYP2C19 – PPIs

CYP2C19 testing was implemented to predict response for gastroenterology patients taking a group of drugs known as proton pump inhibitors.

DNA Helix

2017

PGx Consult Clinic

DNA Helix

2018

CYP2D6 – Opioids (Surgery)

DNA Helix

2019

Panel/Preemptive Testing

DNA Helix

2019

Oncology Supportive Care

DNA Helix

2019

TPMT/NUDT15-Thiopurines

DNA Helix

2020

CYP2C9-NSAIDs

DNA Helix

2023

SLC01B1-statins

DNA Helix

2023

Genomic Indicators

DNA Helix

What is Pharmacogenetics?

Identify the best medicine for you

What is pharmacogenetics?

Pharmacogenetics can affect response, increase effectiveness and decrease side effects to different medications.

Pharmacogenetic testing Play Video

Infectious Disease Pharmacokinetics Laboratory

under the direction of Dr. Charles Peloquin

Infectious Disease Pharmacokinetics Laboratory

The Infectious Disease Pharmacokinetics Laboratory is focused clinically on the treatment of patients with serious infections, including tuberculosis, HIV and fungal infections.

Infectious Disease Pharmacokinetics Laboratory

The Future of Precision Medicine at UF Health

a new era of genetic medicine

Reengineering the clinical environment for precision medicine at UF Health

In 2019, the UF Health Precision Medicine Program launched a multi-gene pharmacogenetics panel developed by UF Health Pathology Laboratories. It examines multiple drugs, multiple genes and, eventually, diseases to personalize drug therapy and disease risk assessment around an individual’s genetic profile.

Rhonda Cooper-DeHoff